Pasar al contenido principal

UTILIZACION DE MEDICINA DE SISTEMAS PARA LA PREDICCION DE LA INMUNOGENICIDAD Y EFICACIA DE VACUNAS TERAPEUTICAS FRENTE A VIH

SAF2015-66193-R

•
Nombre agencia financiadora Ministerio de Economía y Competitividad
Acrónimo agencia financiadora MINECO
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2015
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Unidad de gestión Dirección General de Investigación Científica y Técnica
Centro beneficiario CONSORCI INSTITUT D INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER
Identificador persistente http://dx.doi.org/10.13039/501100003329

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación

Comparison of safety and vector-specific immune responses in healthy and HIV-infected populations vaccinated with MVA-B

  • Couto, Elvira
  • Diaz-Brito, Vicenç
  • Mothe, Beatriz
  • Guardo, Alberto C.
  • Fernández Piñeiro, Irene
  • Ugarte, Ainoa
  • Etcheverry, Flor
  • Gómez, Carmen E.
  • Esteban, Mariano
  • Pich, Judit
  • Arnaiz, Joan Albert
  • López Bernaldo de Quirós, Juan Carlos
  • Brander, Christian
  • Plana, Montserrat
  • García, Felipe
  • Leal, Lorna
There are few studies comparing the safety and immunogenicity of the same HIV immunogen in healthy volunteers and HIV-infected individuals. We analyzed demographics, adverse events (AEs), and immunogenicity against vaccinia virus in preventive (RISVAC02, n = 24 low-risk HIV-negative volunteers) and therapeutic (RISVAC03, n = 20 successfully treated chronically HIV-1-infected individuals) vaccine phase-I clinical trials that were performed with the same design and the same immunogen (modified vaccinia virus Ankara-B: MVA-B). Total AEs were significantly higher in HIV-infected patients (mean AEs/patient 6.6 vs. 12.8 (p < 0.01)). Conversely, the number of AEs related to vaccination (AEsRV) was similar between both groups. No grade III or IV AEsRV were observed in either clinical trial. Regarding the immunogenicity, the proportion of anti-vaccinia virus antibody responders was similar in both studies. Conversely, the magnitude of response was significantly higher in HIV-infected patients (median binding antibodies at w8 267 vs. 1600 U/mL (p = 0.002) and at w18 666 vs. 3200 U/mL (p = 0.003)). There was also a trend towards higher anti-vaccinia virus neutralizing activity in HIV-infected individuals (proportion of responders 37% vs. 63% (p = 0.09); median IC50 32 vs. 64 (p = 0.054)). This study confirms the safety of MVA-B independent of HIV serostatus. HIV-infected patients showed higher immune responses against vaccinia virus., This study was partially supported by grants: the European Commission (grants: H2020-SC1-2016-RTD, Proposal: 731626), the Spanish Ministry of Economy (MINECO) (grants: SAF2015-66193-R, RTI2018-096309-B-I00, EC10-153, TRA-094), the Fondo de Investigación Sanitaria (FIS) (PI15/00480, AC16/00051, and PI18/00699), the Fondo Europeo para el Desarrollo Regional (FEDER), the SPANISH AIDS Research Network RD16/0025/0002–ISCIII—FEDER (RIS), and the CERCA Programme/Generalitat de Catalunya (SGR 615). F.G. has received the support of José María Segovia de Arana contracts. HIVACAT: HIV development program in Catalonia. IDIBAPS: Institut d’Investigacions Biomèdiques August Pi I Sunyer., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Proteomic Profile Associated With Loss of Spontaneous Human Immunodeficiency Virus Type 1 Elite Control

  • Rodríguez-Gallego, Esther
  • Tarancón-Díez, Laura
  • García, Felipe
  • Romero, Jorge del
  • Benito, José Miguel
  • Alba, Verónica
  • Herrero, Pol
  • Rull, Anna
  • Domínguez-Molina, Beatriz
  • Martínez-Madrid, Onofre
  • Martín-Pena, Luisa
  • Pulido, Federico
  • Leon, Agathe
  • Rodríguez, Carmen
  • Rallón, Norma
  • Peraire, Joaquim
  • Viladés, Consuelo
  • Leal, Manuel
  • Vidal, Francesc
  • Ruiz-Mateos, Ezequiel
[Background] Elite controllers (ECs) spontaneously control plasma human immunodeficiency virus type 1 (HIV-1) RNA without antiretroviral therapy. However, 25% lose virological control over time. The aim of this work was to study the proteomic profile that preceded this loss of virological control to identify potential biomarkers., [Methods] Plasma samples from ECs who spontaneously lost virological control (transient controllers [TCs]), at 2 years and 1 year before the loss of control, were compared with a control group of ECs who persistently maintained virological control during the same follow-up period (persistent controllers [PCs]). Comparative plasma shotgun proteomics was performed with tandem mass tag (TMT) isobaric tag labeling and nanoflow liquid chromatography coupled to Orbitrap mass spectrometry., [Results] Eighteen proteins exhibited differences comparing PC and preloss TC timepoints. These proteins were involved in proinflammatory mechanisms, and some of them play a role in HIV-1 replication and pathogenesis and interact with structural viral proteins. Coagulation factor XI, α-1-antichymotrypsin, ficolin-2, 14-3-3 protein, and galectin-3-binding protein were considered potential biomarkers., [Conclusions] The proteomic signature associated with the spontaneous loss of virological control was characterized by higher levels of inflammation, transendothelial migration, and coagulation. Galectin-3 binding protein could be considered as potential biomarker for the prediction of virological progression and as therapeutic target in ECs., This work was supported by grants from the Fondo de Investigación Sanitaria, Instituto de Salud Carlos III, Fondos Europeos para el Desarrollo Regional (grant numbers PI10/02635, PI13/00796, and PI16/00503 to F. V.; PI12/02283, PI16/00684, and CPII014/00025 to E. R.-M.; FI14/00431 to L. T.-D.; and CP14/00198 to N. R.); Programa de Suport als Grups de Recerca (grant numbers 2017SGR948 and 2014SGR250); the Gilead Fellowship Program (grant numbers GLD14/293 and GLD17/00299); the Red de Investigación en Sida (grant numbers RD12/0017/0005, RD16/0025/0006, RD12/0017/0029, RD16/0025/0020, and RD12/0017/0031, RD16/0025/0013); Ministerio de Economia y Competitividad, Spain (grant number SAF2015-66193-R); and the Spanish Ministry of Education (grant number FPU13/02451 to B. D. M). E. R.-M. is supported by Consejería de Salud y Bienestar Social of Junta de Andalucía through the Nicolás Monardes program (C-0032/17). F. V. is supported by a grant from the Programa de Intensificación de Investigadores, Instituto de Salud Carlos III (grant numbers INT11/240, INT12/282, and INT15/226). A. R. is supported by a grant from the Acció Instrumental d’incorporació de científics i tecnòlegs (PERIS SLT002/16/00101), Departament de Salut, Generalitat de Catalunya., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Enhancement of the HIV-1-Specific Immune Response Induced by an mRNA Vaccine through Boosting with a Poxvirus MVA Vector Expressing the Same Antigen

  • Gómez, Carmen E.
  • Perdiguero, Beatriz
  • Usero, Lorena
  • Marcos-Villar, Laura
  • Miralles, Laia
  • Leal, Lorna
  • Sorzano, Carlos Óscar S.
  • Sánchez-Corzo, Cristina
  • Plana, Montserrat
  • García, Felipe
  • Esteban, Mariano
Development of a vaccine against HIV remains a major target goal in the field. The recent success of mRNA vaccines against the coronavirus SARS-CoV-2 is pointing out a new era of vaccine designs against pathogens. Here, we have generated two types of mRNA vaccine candidates against HIV-1; one based on unmodified vectors and the other on 1-methyl-3′-pseudouridylyl modified vectors expressing a T cell multiepitopic construct including protective conserved epitopes from HIV-1 Gag, Pol and Nef proteins (referred to as RNA-TMEP and RNA-TMEPmod, respectively) and defined their biological and immunological properties in cultured cells and in mice. In cultured cells, both mRNA vectors expressed the corresponding protein, with higher levels observed in the unmodified mRNA, leading to activated macrophages with differential induction of innate immune molecules. In mice, intranodal administration of the mRNAs induced the activation of specific T cell (CD4 and CD8) responses, and the levels were markedly enhanced after a booster immunization with the poxvirus vector MVA-TMEP expressing the same antigen. This immune activation was maintained even three months later. These findings revealed a potent combined immunization regimen able to enhance the HIV-1-specific immune responses induced by an mRNA vaccine that might be applicable to human vaccination programs with mRNA and MVA vectors., This study was partially supported by grants from the Spanish Ministry of Economy (MINECO) (grants: SAF2015-66193-R, SAF-2017-88089-R, RTI2018-096309-B-I00); the Fondo Europeo para el Desarrollo Regional (FEDER); the SPANISH AIDS Research Network RD16/0025/0002 and RD16/0025/0014-ISCIII-FEDER (RIS); the Fondo de Investigación Sanitaria (FIS) AC16/00051 and PI18/00699; the Instituto de Salud Carlos III (grants: COV20/00214; ICI20/00067) and the CERCA Programme/Generalitat de Catalunya SGR 615 and SGR 653. This manuscript was funded by the European Commission [grant numbers: FP7-HEALTH-2013-INNOVATION-1 602570-2, H2020-SC1- 2016-2017 (H2020-SC1-2016-RTD) Proposal: 731626-HIVACAR]., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Adherence to a Supplemented Mediterranean Diet Drives Changes in the Gut Microbiota of HIV-1-Infected Individuals

  • Pastor-Ibáñez, Roque|||0000-0002-0787-4638
  • Blanco-Heredia, Juan|||0000-0001-9526-7450
  • Etcheverry, Florencia
  • Sánchez-Palomino, Sonsoles
  • Díez-Fuertes, Francisco|||0000-0003-2413-9229
  • Casas, Rosa|||0000-0002-0211-9166
  • Navarrete-Muñoz, María Ángeles
  • Castro Barquero, Sara|||0000-0002-6876-5443
  • Lucero, Constanza
  • Fernandez, Irene
  • Leal, Lorna|||0000-0001-7887-6027
  • Benito, José Miguel|||0000-0002-7172-049X
  • Noguera-Julian, Marc|||0000-0002-6194-1395
  • Paredes, Roger|||0000-0002-6553-691X
  • Rallón, Norma|||0000-0002-4643-247X
  • Estruch, Ramón|||0000-0003-1260-4445
  • Torrents, David|||0000-0002-6086-9037
  • García, Felipe|||0000-0001-7658-5832
Objective: The health effects of a supplemented Mediterranean diet (SMD) with extra-virgin olive oil (EVOO) and nuts are well documented in non-HIV-infected individuals. We hypothesised that the benefits of an SMD could be mediated by changes in the gut microbiota, even in those with an altered intestinal microbiota such as people living with HIV. Design: Individuals living with HIV (n = 102) were randomised to receive an SMD with 50 g/day of EVOO and 30 g/day of walnuts (SMD group) or continue with their regular diet (control group) for 12 weeks. Methods: Adherence to the Mediterranean diet was assessed using the validated 14-item MD-Adherence-Screener (MEDAS) from the PREDIMED study. A sub-study classifying the participants according to their MEDAS scores was performed. Results: The lipid profile was improved in the SMD group vs. that in the control group (delta-total cholesterol and delta-B-lipoprotein). The immune activation (CD4+HLADR+CD38+ and CD8+HLADR+CD38+ cells) and IFN-γ-producing T-cells significantly decreased at week 12 compared to the baseline in the SMD group but not in the control group. The gut microbiota in those from the high-adherence group presented significantly high diversity and richness at the end of the intervention. Succinivibrio and Bifidobacterium abundances were influenced by the adherence to the MD and significantly correlated with Treg cells. Conclusion: The Mediterranean diet improved metabolic parameters, immune activation, Treg function, and the gut microbiota composition in HIV-1-infected individuals. Further, Mediterranean diet increased the Bifidobacterium abundances after the intervention, and it was associated to a beneficial profile.